Valuation : Bioventix PLC

Market Cap 90.39M 122M 105M 98.8M 169M 11.57B 170M 1.17B 455M 5.91B 459M 449M 19.04B P/E 2026 *
12.9x
P/E 2027 * -
Enterprise Value 85.5M 116M 99.58M 93.45M 160M 10.94B 161M 1.11B 431M 5.59B 435M 425M 18.01B EV / Sales 2026 *
6.84x
EV / Sales 2027 * -
Free-Float
92.29%
Yield 2026 *
8.67%
Yield 2027 * -
1 month+14.57%
3 months+4.22%
6 months+19.31%
Current year-9.19%
1 week 1,660
Extreme 1660
1,800
1 month 1,450
Extreme 1450
1,800
Current year 1,300
Extreme 1300
1,950
1 year 1,300
Extreme 1300
2,550
3 years 1,300
Extreme 1300
5,100
5 years 1,300
Extreme 1300
5,100
10 years 26.51
Extreme 26.51
5,100
Manager TitleAgeSince
Chief Executive Officer 67 2003-12-22
Director of Finance/CFO 67 2020-06-30
Director TitleAgeSince
Director/Board Member 67 2010-11-24
Chairman 66 2004-10-31
Director/Board Member 67 2020-06-30
Date Insider Type Main position Quantity % Market Cap. Importance
4/28/26 Buy

Chief Financial Officer

66 0.0013%
4/20/26 Free

Chief Executive Officer

9,967 0.1908%
4/20/26 Free

Chief Financial Officer

9,967 0.1908%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-29.96%-54.47% 122M
-0.24%-1.09%+2.00%+18.17% 50.35B
+0.78%-4.65%+430.22%+501.63% 45.2B
+2.95%+3.52%+47.12%+21.08% 44.71B
+0.25%-2.63%+7.86%+73.60% 41.24B
+0.43%-2.20%+14.55%+49.08% 33.08B
+1.43%+8.73% - - 17.81B
+0.06%-2.97%+23.31%+116.96% 16.56B
+0.93%+0.63%+16.86%+29.70% 14.82B
+0.54%-1.03%+80.71%+39.94% 14B
Average +0.71%-0.14%+65.85%+88.41% 27.79B
Weighted average by Cap. +0.82%-0.64%+93.13%+123.49%

Financials

2026 *2027 *
Net sales 12.5M 16.92M 14.56M 13.66M 23.33M 1.6B 23.52M 162M 62.94M 817M 63.54M 62.16M 2.63B -
Net income 7.11M 9.63M 8.28M 7.77M 13.27M 910M 13.38M 91.96M 35.81M 465M 36.15M 35.36M 1.5B -
Net Debt -4.89M -6.62M -5.7M -5.35M -9.13M -626M -9.21M -63.28M -24.64M -320M -24.88M -24.34M -1.03B -
Logo Bioventix PLC
Bioventix plc is a United Kingdom-based company specializing in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, such as automated immunoassays used in blood testing. The antibodies created at the Company are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes, for the diagnosis or monitoring of a range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. The Company’s products include sheep monoclonal antibodies (SMAs), Pyrene (HOP-G) ELISA Kits, and Pyrene (HOP-G) Lateral Flow Kits. The Company supplies antibody products and services to the majority of multinational clinical diagnostics companies.
Employees
12
Date Price Change Volume
26-09-03 GBX 1,730.00 0.00% 5,574
26-09-02 GBX 1,730.00 +0.29% 3,359
26-09-01 GBX 1,725.00 -0.29% 5,061
26-08-28 GBX 1,730.00 0.00% 5,360
26-08-27 GBX 1,730.00 -1.14% 4,205
Trader
Investor
Global
-
Quality
ESG MSCI
CCC

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BVXP Stock